• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

青少年和青年霍奇金淋巴瘤患者的多学科管理

Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma.

作者信息

Galloway Emily, Griffith Melody, Rosenthal Allison

机构信息

University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.

Mayo Clinic Division of Hematology and Medical Oncology, Phoenix, AZ, USA.

出版信息

Curr Treat Options Oncol. 2021 Jun 7;22(7):64. doi: 10.1007/s11864-021-00861-0.

DOI:10.1007/s11864-021-00861-0
PMID:34097142
Abstract

Successful management of adolescent and young adult patients with Hodgkin lymphoma (HL) requires a multidisciplinary approach to care with special attention paid to the unique medical, logistical, and psychosocial challenges faced by this group. The emotional and social changes and big life transitions that occur between the ages of 15 and 39 result in a broad scope of supportive care needs that differ from children or adults in similar circumstances. Currently, care of adolescent and young adult (AYA) patients with HL may be fractured across the pediatric-adult cancer care continuum resulting in this group being less well studied than pediatric or adult patients in general. In order to optimize outcomes, these patients need access to medical oncologists and radiation oncologists, advanced practice providers (APPs), psychologists/social work, financial support services, fertility specialists, survivorship care, and advocates with AYA expertise that can help navigate the healthcare system. A strong AYA support system established early with targeted education and resources may influence treatment compliance and likelihood of long-term follow-up. Surveys of the AYA cancer population have identified areas of opportunity for the healthcare team to collaborate to identify needs, design interventions to meet them, and ultimately develop evidence-based guidelines that will enable us to offer AYAs with HL the quality care they deserve.

摘要

成功管理青少年和青年霍奇金淋巴瘤(HL)患者需要多学科的护理方法,特别关注该群体所面临的独特医学、后勤和社会心理挑战。15至39岁之间发生的情绪和社会变化以及重大的人生转变导致了广泛的支持性护理需求,这与处于类似情况的儿童或成年人不同。目前,青少年和青年(AYA)HL患者的护理可能在儿科 - 成人癌症护理连续体中出现脱节,导致该群体总体上比儿科或成人患者研究得更少。为了优化治疗效果,这些患者需要接触医学肿瘤学家、放射肿瘤学家、高级执业提供者(APP)、心理学家/社会工作者、财务支持服务、生育专家、生存护理以及具有AYA专业知识的倡导者,以帮助他们在医疗保健系统中顺利就医。早期建立一个强大的AYA支持系统,并提供有针对性的教育和资源,可能会影响治疗依从性和长期随访的可能性。对AYA癌症患者群体的调查确定了医疗团队合作的机会领域,以识别需求、设计满足需求的干预措施,并最终制定基于证据的指南,使我们能够为患有HL的AYA患者提供他们应得的优质护理。

相似文献

1
Multidisciplinary Management of Adolescent and Young Adult Patients with Hodgkin Lymphoma.青少年和青年霍奇金淋巴瘤患者的多学科管理
Curr Treat Options Oncol. 2021 Jun 7;22(7):64. doi: 10.1007/s11864-021-00861-0.
2
Adolescent and young adult Hodgkin lymphoma: Raising the bar through collaborative science and multidisciplinary care.青少年和年轻成人霍奇金淋巴瘤:通过协作科学和多学科护理提高标准。
Pediatr Blood Cancer. 2018 Jul;65(7):e27033. doi: 10.1002/pbc.27033. Epub 2018 Mar 30.
3
AYA Considerations for Aggressive Lymphomas.青少年和年轻成人弥漫大 B 细胞淋巴瘤的临床特征和治疗。
Curr Hematol Malig Rep. 2021 Feb;16(1):61-71. doi: 10.1007/s11899-021-00607-7. Epub 2021 Mar 16.
4
Adolescents and young adults with classical Hodgkin lymphoma in northern Tunisia: insights from an adult single-institutional study.突尼斯北部经典型霍奇金淋巴瘤青少年及青年患者:一项成人单机构研究的见解
Cancer Radiother. 2020 Jun;24(3):206-214. doi: 10.1016/j.canrad.2020.01.004. Epub 2020 Mar 11.
5
Identifying and Meeting the Needs of Adolescents and Young Adults with Cancer.识别和满足癌症青少年和青年的需求。
Curr Oncol Rep. 2021 Jan 15;23(2):17. doi: 10.1007/s11912-020-01011-9.
6
Treatment patterns and outcomes in adolescents and young adults with Hodgkin lymphoma in pediatric versus adult centers: An IMPACT Cohort Study.青少年和青年霍奇金淋巴瘤患者在儿科和成人中心的治疗模式和结局:IMPACT 队列研究。
Cancer Med. 2020 Oct;9(19):6933-6945. doi: 10.1002/cam4.3138. Epub 2020 May 22.
7
Use of recommended posttreatment services for adolescent and young adult survivors of Hodgkin lymphoma.青少年及青年霍奇金淋巴瘤幸存者推荐的治疗后服务的使用。
Cancer. 2019 May 1;125(9):1558-1567. doi: 10.1002/cncr.31953. Epub 2019 Jan 8.
8
Classic Hodgkin Lymphoma in Adolescents and Young Adults.青少年和青年经典型霍奇金淋巴瘤。
J Clin Oncol. 2024 Feb 20;42(6):653-664. doi: 10.1200/JCO.23.01799. Epub 2023 Nov 20.
9
Outcome of adolescents and young adults compared to children with Hodgkin lymphoma treated with response-based chemotherapy on pediatric protocols: A Children's Oncology Group report.与采用基于反应的化疗方案按照儿科方案治疗的儿童霍奇金淋巴瘤患者相比,青少年和青年成人患者的治疗结果:一份儿童肿瘤学组报告。
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26681. Epub 2017 Jun 14.
10
An Age Stratified Analysis of the Access to Care Continuum Across Three Tumor Groups: Are There Delays for AYA?按年龄分层分析三个肿瘤群组的就诊连续性:青少年和年轻成人是否存在就诊延误?
J Adolesc Young Adult Oncol. 2019 Aug;8(4):402-409. doi: 10.1089/jayao.2018.0126. Epub 2019 Mar 26.

引用本文的文献

1
Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy.布伦妥昔单抗诱导的周围神经毒性:应对霍奇金淋巴瘤治疗新挑战的多学科方法
Cancers (Basel). 2021 Dec 5;13(23):6125. doi: 10.3390/cancers13236125.

本文引用的文献

1
Evaluation of Reported Fertility Preservation Counseling Before Chemotherapy Using the Quality Oncology Practice Initiative Survey.采用肿瘤质量实践倡议调查评估化疗前报告的生育力保存咨询情况。
JAMA Netw Open. 2020 Jul 1;3(7):e2010806. doi: 10.1001/jamanetworkopen.2020.10806.
2
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.KTE-X19 嵌合抗原受体 T 细胞疗法治疗复发或难治性套细胞淋巴瘤。
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
3
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
纳武利尤单抗治疗复发或难治性实体瘤或淋巴瘤的儿童和青年患者(ADVL1412):一项多中心、开放标签、单臂、1-2 期临床试验。
Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17.
4
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.贝林妥欧单抗联合化疗治疗 III/IV 期经典型霍奇金淋巴瘤:ECHELON-1 研究 3 年更新结果。
Blood. 2020 Mar 5;135(10):735-742. doi: 10.1182/blood.2019003127.
5
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.帕博利珠单抗治疗晚期黑色素瘤或 PD-L1 阳性、晚期、复发、难治性实体瘤或淋巴瘤的儿科患者(KEYNOTE-051):一项开放标签、单臂、1-2 期临床试验的中期分析。
Lancet Oncol. 2020 Jan;21(1):121-133. doi: 10.1016/S1470-2045(19)30671-0. Epub 2019 Dec 4.
6
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.正电子发射断层扫描指导早期有利型霍奇金淋巴瘤治疗:德国霍奇金研究组国际、随机 III 期 HD16 试验的最终结果。
J Clin Oncol. 2019 Nov 1;37(31):2835-2845. doi: 10.1200/JCO.19.00964. Epub 2019 Sep 10.
7
Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach.保存血液系统恶性肿瘤女性患者的生育能力:多学科肿瘤生育学方法。
Ann Oncol. 2019 Nov 1;30(11):1760-1775. doi: 10.1093/annonc/mdz284.
8
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study.PET 指导下治疗新诊断的晚期霍奇金淋巴瘤(AHL2011):一项随机、多中心、非劣效性、3 期研究。
Lancet Oncol. 2019 Feb;20(2):202-215. doi: 10.1016/S1470-2045(18)30784-8. Epub 2019 Jan 15.
9
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
10
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.维布妥昔单抗治疗儿童复发或难治性霍奇金淋巴瘤及间变性大细胞淋巴瘤:一项多中心、开放标签的1/2期研究。
Lancet Haematol. 2018 Oct;5(10):e450-e461. doi: 10.1016/S2352-3026(18)30153-4.